Postdoctoral Fellow – Genome Editing and Small Molecule Therapy
Duke University, Durham, NC
Salary commensurate with experience, includes excellent benefits.
Postdoctoral position available immediately for research on genome editing in rare genetic diseases. Genome editing with adeno-associated virus vectors is a major focus of the laboratory. The project will include in vivo genome editing to treat glycogen storage disease (GSD), either GSD type Ia or type II (Pompe disease). A second focus is to develop small molecules to stimulate autophagy and reverse the abnormalities of autophagy in GSDs. New drug therapy for GSDs will have implications for the treatment of more common conditions, including non-alcoholic fatty liver disease and diabetic nephropathy. Representative publications describe the scope of this project [1-6]. Duke University features outstanding clinical and scientific resources with opportunities for local and international collaboration. This position will support an active collaboration with established genome editing, autophagy, and virology research groups. Candidates with molecular biology experience, and familiarity with viral vectors, immunology, and/or biochemistry are encouraged to apply. Ph.D. and/or M.D. required. The position is located in Dwight Koeberl’s laboratory in the Department of Pediatrics/Division of Medical Genetics, and the Department of Molecular Genetics and Microbiology at Duke University School of Medicine.
Website: https://scholars.duke.edu/display/per3329362
Interested candidates should submit their electronic application to dwight.koeberl@duke.edu that should include: (1) the names of 3 references, and (2) an updated CV.
References
1 Farah, B. L. et al. Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency. J Hepatol 64, 370-379, doi:10.1016/j.jhep.2015.10.008 (2016).
2 Farah, B. L. et al. Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa). Sci Rep 7, 44408, doi:10.1038/srep44408 (2017).
3 Landau, D. J. et al. In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA. Mol Ther 24, 697-706, doi:10.1038/mt.2016.35 (2016).
4 Waskowicz, L. R. et al. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia. Hum Mol Genet 28, 143-154, doi:10.1093/hmg/ddy343 (2019).
5 Kang, H. R. et al. Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia. Mol Ther Methods Clin Dev 13, 265-273, doi:10.1016/j.omtm.2019.02.002 (2019).
6 Yavarow, Z. A. et al. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. Hum Mol Genet 29, 286-294, doi:10.1093/hmg/ddz290 (2020).
Duke University is an Affirmative Action/Equal Opportunity Employer committed to providing employment opportunity without regard to an individual's age, color, disability, gender, gender expression, gender identity, genetic information, national origin, race, religion, sex, sexual orientation, or veteran status.
Duke aspires to create a community built on collaboration, innovation, creativity, and belonging. Our collective success depends on the robust exchange of ideas-an exchange that is best when the rich diversity of our perspectives, backgrounds, and experiences flourishes. To achieve this exchange, it is essential that all members of the community feel secure and welcome, that the contributions of all individuals are respected, and that all voices are heard. All members of our community have a responsibility to uphold these values. |